NIDA Avant-Garde Award

NIDA Avant-Garde Award

Offers support for innovative researchers pursuing high-impact HIV and substance use science across career stages.

The NIDA Avant-Garde Award uses the DP1 mechanism — a NIH Director's Pioneer-style grant — to fund exceptionally creative scientists pursuing high-impact research at the intersection of HIV and substance use. Unlike most NIH mechanisms, the Avant-Garde is open to investigators at all career levels, from early-stage researchers to established senior scientists. The program targets transformative approaches that open new areas of HIV research or establish new prevention and treatment avenues for people who use drugs. NIDA administers this award through its HIV Research Program.

Applicants must be affiliated with a U.S. research organization, university, or nonprofit institution. For-profit companies are not eligible as lead applicants. Award amounts and specific cycle dates are published in the funding opportunity announcement and in a 924KB applicant PDF guide available from NIDA; these figures were not captured in currently available source pages. The DP1 mechanism is intentionally flexible — it supports the investigator's research vision rather than constraining work to a predefined scope, making preliminary data less central to scoring than in standard R01 applications.

Competition is characteristically intense because the program specifically seeks work that departs from existing paradigms. Reviewers evaluate scientific creativity and potential for paradigm-shifting impact alongside feasibility. Applicants should consult the current NIDA funding opportunity announcement on grants.nih.gov for active submission dates and budget guidance. Contact NIDA's HIV Research Program office for pre-application alignment discussions. The Avant-Garde complements NIDA's Avenir Award (DP2), which is restricted to early-stage investigators — teams with established PIs should apply to Avant-Garde rather than Avenir.